<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: <z:hpo ids='HP_0003741'>Congenital muscular dystrophies</z:hpo> (CMD) with hypoglycosylated α-dystroglycan due to POMT1 mutations are associated with clinical phenotypes that vary in severity </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: We describe a patient with congenital <z:hpo ids='HP_0001290'>hypotonia, generalized</z:hpo> <z:mp ids='MP_0000746'>weakness</z:mp>, <z:hpo ids='HP_0003236'>elevated creatine kinase</z:hpo> (CK), and <z:mpath ids='MPATH_458'>normal</z:mpath> brain imaging </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Histochemical analysis of the index case's muscle showed deficiency of glycosylated α-dystroglycan and secondary merosin deficiency </plain></SENT>
<SENT sid="3" pm="."><plain>Genetic testing revealed a novel mutation in exon 20 of the POMT1 gene </plain></SENT>
<SENT sid="4" pm="."><plain>CONCLUSIONS: Our patient's milder form of CMD adds to the emerging evidence of an expanding phenotype caused by POMT1 mutations </plain></SENT>
<SENT sid="5" pm="."><plain>The histopathological findings of the muscle biopsy in this case support the need for careful clinical, genetic, and histochemical diagnostic interpretation </plain></SENT>
</text></document>